CGI-1746

• Description :

  CGI-1746 is a potent and highly selective inhibitor of the Btk with IC50 of 1.9 nM.

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Autophagy; Btk

• Type :

  Reference compound

• Related Pathways :

  Autophagy; Protein Tyrosine Kinase/RTK

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/CGI-1746.html

• Concentration :

  10mM

• Purity :

  99.39

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  O=C(C1=CC=C(C=C1)C(C)(C)C)NC2=CC=CC(C(N=C3NC4=CC=C(C=C4)C(N5CCOCC5)=O)=CN(C3=O)C)=C2C

• Molecular Formula :

  C34H37N5O4

• Molecular Weight :

  579.69

• Precautions :

  H302

• References & Citations :

  [1]Di Paolo, Julie A. et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nature Chemical Biology (2011), 7 (1), 41-50|[2]Kokabee L, et al. Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biol Ther. 2015;16 (11) :1604-15

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [910232-84-7]